Carnosic Acid — Safety, Research, Risks & Legal Status

Not medical advice. Carnosic Acid is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Salvin; diAcCA (semi-synthetic pro-drug derivative); CAS 3650-09-7
Category	Supplement
Chemical class	Abietane-type phenolic diterpene
Molecular formula	C20H28O4 (MW 332.43 g/mol)
Natural source	Rosemary (Rosmarinus officinalis) and sage (Salvia officinalis)
Primary mechanism	KEAP1/Nrf2 pathway activation via S-alkylation of KEAP1 cysteine residues
Pro-drug derivative	diAcCA (diacetate pro-drug, Scripps Research, 2025) — preclinical only
Regulatory status (US)	GRAS as food additive; not approved as a drug; diAcCA has no FDA designation
US legal status	Carnosic acid itself holds FDA GRAS (Generally Recognized as Safe) status as a food additive and botanical extract; it is not regulated as a drug. It is commercially available as a rosemary or sage extract. The semi-synthetic derivative diAcCA is an experimental compound with no FDA IND filing, designation, or approval pathway publicly disclosed as of mid-2025. Neither carnosic acid nor diAcCA has been approved for any clinical indication.

What is Carnosic Acid?

Carnosic acid is an abietane-type phenolic diterpene found naturally in rosemary (Rosmarinus officinalis) and sage (Salvia officinalis). It is a well-characterized antioxidant and anti-inflammatory natural compound whose primary mechanism of action centers on activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) cytoprotective pathway. Interest in carnosic acid as a standalone therapeutic is preclinical; its poor bioavailability and chemical instability in physiological conditions led Scripps Research to develop diAcCA, a stabilized diacetate pro-drug that converts to carnosic acid in the gut. As of 2025, both carnosic acid and diAcCA remain in preclinical stages with no registered human trials.

How it works

Carnosic acid is a Nrf2 pathway activator. It S-alkylates specific cysteine residues on the KEAP1 repressor protein, releasing Nrf2 to translocate to the nucleus and drive transcription of phase 2 antioxidant and cytoprotective enzymes including superoxide dismutase (SOD), catalase, and NQO1. RNAi knockdown experiments have confirmed that Nrf2 is required for carnosic acid's neuroprotective effect - abrogating Nrf2 expression eliminates the protective signal. Secondary mechanisms include suppression of NLRP3 inflammasome activation and attenuation of neuroinflammatory signaling. Carnosic acid crosses the blood-brain barrier upon oral dosing and accumulates in brain tissue in animal models, enabling local CNS activity. diAcCA functions as a masked form of carnosic acid, releasing the active compound after intestinal hydrolysis while offering improved stability relative to the parent molecule.

Background & history

Carnosic acid has been studied as a natural antioxidant constituent of culinary herbs for decades. Academic work, primarily at Scripps Research, UC San Diego, and the University of Kentucky, characterized its Nrf2-centric mechanism in the 2010s. The recognition that its instability limited drug development potential prompted the synthesis of diAcCA, a diacetate pro-drug disclosed by Stuart Lipton's group at Scripps Research. In February 2025, results of diAcCA in the 5xFAD transgenic Alzheimer's mouse model were published in Antioxidants (PMC11939361). Lipton's team expressed intent to pursue clinical trials on an accelerated basis, with co-author affiliations noting Socrates Biosciences involvement, though no formal IND filing or trial registration has been publicly announced as of mid-2025.

What the research says

All human-relevant evidence is indirect or extrapolated from preclinical work. No clinical trials for carnosic acid or diAcCA as standalone compounds are registered on ClinicalTrials.gov (seven ongoing rosemary-extract trials exist for unrelated indications but are not carnosic-acid-specific). In vitro studies demonstrate neuroprotection in primary cerebellar granule neurons and other neuronal cultures against oxidative and excitotoxic insult via Nrf2 induction. In the 5xFAD transgenic Alzheimer's mouse model, diAcCA treatment improved memory performance, increased synaptic density, and reduced amyloid-beta plaque burden, phospho-tau tangles, and neuroinflammatory markers including astrocyte and microglial activation markers (Antioxidants, 2025). The Keap1/Nrf2 S-alkylation mechanism has been characterized in vitro and in rodent models. No peer-reviewed human efficacy or pharmacokinetic data for carnosic acid as a neuroactive compound exists in the published literature reviewed for this entry. Generalization from mouse Alzheimer's models to humans carries well-recognized limitations.

Reported effects

Nrf2 pathway activation with induction of phase 2 antioxidant enzymes (SOD, catalase, NQO1) — established in vitro and in animal models
NLRP3 inflammasome suppression and attenuation of neuroinflammatory signaling — preclinical animal data
Blood-brain barrier penetration and CNS accumulation upon oral dosing — demonstrated in rodent pharmacokinetic studies
Reduction of amyloid-beta plaques and phospho-tau tangles in transgenic Alzheimer's mice (diAcCA pro-drug, 5xFAD model) — preclinical only, no human data
Improved memory performance in Alzheimer's mouse model (diAcCA) — preclinical only, no human data
Neuroprotection against oxidative and excitotoxic insult in neuronal cell cultures — in vitro only

Dosing & administration (informational)

Published preclinical literature uses variable dosing regimens in rodent models; these cannot be directly extrapolated to human dosing by weight without human pharmacokinetic data, which does not yet exist for carnosic acid as a neuroactive compound. No established human therapeutic dose exists. Rosemary extract supplements on the consumer market are not standardized for carnosic acid content in a clinically meaningful way. This field is informational only; it is not a dosing protocol. Anyone considering use for any medical purpose should consult a licensed clinician.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Acute LD50 approximately 7,100 mg/kg in rats — low acute toxicity concern based on animal data
Chronic high-dose animal studies showed mild weight loss and slight cardiac, hepatic, and renal pathology — clinical significance in humans unknown
Dose-dependent diarrhea observed in rodent studies
High-dose rosemary essential oil has antigonadotrophic effects in mice; relevance to isolated carnosic acid supplementation is unclear
Human safety data for isolated carnosic acid at supplemental or therapeutic doses is minimal; rosemary extract clinical trials have not reported significant adverse events, but these are not equivalent exposures
Carnosic acid's chemical instability and relatively low bioavailability in native form are documented limitations — the development of diAcCA was motivated in part by these pharmacokinetic liabilities
No human toxicology studies for diAcCA have been published

Drug & supplement interactions

N
o
h
u
m
a
n
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
o
r
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
s
p
e
c
i
f
i
c
t
o
c
a
r
n
o
s
i
c
a
c
i
d
i
s
a
v
a
i
l
a
b
l
e
i
n
t
h
e
p
u
b
l
i
s
h
e
d
l
i
t
e
r
a
t
u
r
e
r
e
v
i
e
w
e
d
.
G
i
v
e
n
i
t
s
N
r
f
2
a
c
t
i
v
a
t
i
o
n
m
e
c
h
a
n
i
s
m
,
t
h
e
o
r
e
t
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
d
r
u
g
s
t
h
a
t
a
r
e
s
u
b
s
t
r
a
t
e
s
o
f
N
r
f
2
-
r
e
g
u
l
a
t
e
d
p
h
a
s
e
2
e
n
z
y
m
e
s
(
i
n
c
l
u
d
i
n
g
c
e
r
t
a
i
n
c
h
e
m
o
t
h
e
r
a
p
e
u
t
i
c
s
,
h
e
p
a
t
i
c
a
l
l
y
m
e
t
a
b
o
l
i
z
e
d
d
r
u
g
s
)
c
a
n
n
o
t
b
e
e
x
c
l
u
d
e
d
b
u
t
a
r
e
u
n
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
h
u
m
a
n
s
.
R
o
s
e
m
a
r
y
e
x
t
r
a
c
t
s
h
a
v
e
b
e
e
n
n
o
t
e
d
i
n
s
o
m
e
i
n
v
i
t
r
o
s
t
u
d
i
e
s
t
o
m
o
d
u
l
a
t
e
c
y
t
o
c
h
r
o
m
e
P
4
5
0
a
c
t
i
v
i
t
y
;
w
h
e
t
h
e
r
t
h
i
s
i
s
r
e
l
e
v
a
n
t
t
o
c
a
r
n
o
s
i
c
a
c
i
d
s
p
e
c
i
f
i
c
a
l
l
y
a
t
a
c
h
i
e
v
a
b
l
e
c
o
n
c
e
n
t
r
a
t
i
o
n
s
i
n
h
u
m
a
n
s
i
s
u
n
k
n
o
w
n
.
N
o
c
l
i
n
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
s
h
o
u
l
d
b
e
i
n
f
e
r
r
e
d
f
r
o
m
p
r
e
c
l
i
n
i
c
a
l
f
i
n
d
i
n
g
s
w
i
t
h
o
u
t
h
u
m
a
n
s
t
u
d
y
c
o
n
f
i
r
m
a
t
i
o
n
.

Who should avoid it

Pregnancy and lactation — no safety data; antigonadotrophic signals in high-dose animal studies warrant caution
Concurrent use with chemotherapy or narrow therapeutic index drugs without clinician oversight — theoretical Nrf2/phase 2 enzyme interactions uncharacterized in humans
Supra-physiologic or high-dose concentrated extract use without medical supervision given absence of human dose-ranging or toxicology studies
Substituting carnosic acid supplementation for evaluated Alzheimer's therapies — no human efficacy data exists

How it is commonly combined

No clinical stacking data exists. Academic research has compared neuroprotective profiles of carnosic acid against other rosemary-derived phenolics such as rosmarinic acid; these compounds share some overlapping antioxidant mechanisms but have distinct pharmacology. No evidence-based combination rationale for human use can be drawn from available preclinical data.

Legal & regulatory. Carnosic acid itself holds FDA GRAS (Generally Recognized as Safe) status as a food additive and botanical extract; it is not regulated as a drug. It is commercially available as a rosemary or sage extract. The semi-synthetic derivative diAcCA is an experimental compound with no FDA IND filing, designation, or approval pathway publicly disclosed as of mid-2025. Neither carnosic acid nor diAcCA has been approved for any clinical indication.

Quality & harm reduction

C
a
r
n
o
s
i
c
a
c
i
d
i
s
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
a
s
a
r
o
s
e
m
a
r
y
o
r
s
a
g
e
e
x
t
r
a
c
t
i
n
v
a
r
y
i
n
g
s
t
a
n
d
a
r
d
i
z
e
d
c
o
n
c
e
n
t
r
a
t
i
o
n
s
.
A
s
a
b
o
t
a
n
i
c
a
l
e
x
t
r
a
c
t
,
p
r
o
d
u
c
t
p
u
r
i
t
y
a
n
d
c
a
r
n
o
s
i
c
a
c
i
d
c
o
n
t
e
n
t
v
a
r
y
s
u
b
s
t
a
n
t
i
a
l
l
y
b
y
s
u
p
p
l
i
e
r
.
N
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
p
r
e
p
a
r
a
t
i
o
n
f
o
r
h
u
m
a
n
u
s
e
h
a
s
b
e
e
n
a
p
p
r
o
v
e
d
o
r
s
t
a
n
d
a
r
d
i
z
e
d
.
R
e
s
e
a
r
c
h
-
g
r
a
d
e
c
a
r
n
o
s
i
c
a
c
i
d
i
s
a
v
a
i
l
a
b
l
e
f
r
o
m
c
h
e
m
i
c
a
l
s
u
p
p
l
i
e
r
s
(
e
.
g
.
,
S
e
l
l
e
c
k
C
h
e
m
i
c
a
l
s
)
f
o
r
l
a
b
o
r
a
t
o
r
y
u
s
e
.
d
i
A
c
C
A
e
x
i
s
t
s
o
n
l
y
a
s
a
r
e
s
e
a
r
c
h
c
o
m
p
o
u
n
d
d
e
v
e
l
o
p
e
d
a
t
S
c
r
i
p
p
s
R
e
s
e
a
r
c
h
w
i
t
h
n
o
c
o
m
m
e
r
c
i
a
l
a
v
a
i
l
a
b
i
l
i
t
y
.
C
o
n
s
u
m
e
r
s
s
o
u
r
c
i
n
g
r
o
s
e
m
a
r
y
e
x
t
r
a
c
t
s
u
p
p
l
e
m
e
n
t
s
a
s
a
p
r
o
x
y
s
h
o
u
l
d
n
o
t
e
t
h
a
t
t
h
e
c
a
r
n
o
s
i
c
a
c
i
d
f
r
a
c
t
i
o
n
,
t
h
e
e
x
a
c
t
s
t
a
n
d
a
r
d
i
z
a
t
i
o
n
,
a
n
d
t
h
e
b
i
o
a
v
a
i
l
a
b
i
l
i
t
y
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
m
a
y
d
i
f
f
e
r
m
a
t
e
r
i
a
l
l
y
f
r
o
m
t
h
e
c
o
m
p
o
u
n
d
s
s
t
u
d
i
e
d
i
n
p
u
b
l
i
s
h
e
d
p
r
e
c
l
i
n
i
c
a
l
r
e
s
e
a
r
c
h
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is carnosic acid approved to treat Alzheimer's disease?

No. Neither carnosic acid nor its pro-drug derivative diAcCA has been approved for any clinical indication. All efficacy data comes from cell culture and transgenic mouse models. No human trials have been registered as of mid-2025.

What is diAcCA and how does it relate to carnosic acid?

diAcCA is a diacetate pro-drug of carnosic acid developed at Scripps Research to address the poor stability and bioavailability of native carnosic acid. It converts to carnosic acid after intestinal hydrolysis. In the 5xFAD Alzheimer's mouse model (2025 publication), diAcCA reduced amyloid-beta plaques, phospho-tau, and neuroinflammation and improved memory performance. It has not been tested in humans.

Can I take rosemary extract as a substitute for diAcCA?

Rosemary extract supplements contain variable amounts of carnosic acid depending on standardization. The published preclinical research used defined, purified compounds under controlled conditions. Consumer rosemary extracts have not been studied for the neurological endpoints evaluated in diAcCA research, and dose, bioavailability, and composition differ materially. No substitution can be justified from available evidence.

What is the recommended dose of carnosic acid?

No evidence-based human dosing protocol exists for carnosic acid as a therapeutic compound. Human pharmacokinetic and dose-finding studies have not been published. Rodent-derived doses cannot be reliably extrapolated to humans without human PK data. Consult a clinician before use for any medical purpose.

Is carnosic acid safe for human consumption?

Carnosic acid from rosemary and sage has GRAS status from the FDA as a food additive, meaning it is considered safe at levels used in food. Acute animal toxicity is low (LD50 ~7,100 mg/kg in rats). However, human safety data for isolated carnosic acid at supplemental doses is minimal, and chronic high-dose animal studies showed mild organ pathology. High-dose use outside food-additive ranges is not well characterized in humans.

Are there ongoing human clinical trials for carnosic acid?

As of mid-2025, no clinical trials specifically studying carnosic acid or diAcCA as standalone compounds are registered on ClinicalTrials.gov. Several trials of rosemary extract for other indications exist but are not equivalent. Scripps Research has stated intent to pursue clinical trials for diAcCA in Alzheimer's disease, but no IND filing or trial registration has been publicly announced.

References & further reading

PubMed: carnosic acid Keap1 Nrf2 S-alkylation mechanism neuroprotection (see PMC4566957)
PubMed: diAcCA diacetate carnosic acid 5xFAD Alzheimer's mouse model Lipton Scripps 2025 (see PMC11939361)
PubMed: carnosic acid neuroprotective mechanisms review (see PMC10005014)
PubMed: rosemary diterpene Nrf2 NLRP3 inflammasome antioxidant review (MDPI Antioxidants 2022)
ClinicalTrials.gov: carnosic acid OR rosemary extract neuroprotection Alzheimer (no carnosic-acid-specific trials active as of 2025 search)